1. Introduction
The genus
Cyprinivirus (recently renamed
Cyvirus) belongs to the family
Alloherpesviridae of the order
Herpesvirales. This genus comprises alloherpesviruses of cyprinids (
Cyprinid herpesvirus 1,
2, and
3 (CyHV-1, -2, and -3), recently renamed
Cyvirus cyprinidallo 1,
2, and
3)) and anguillid eels (
Anguillid herpesvirus 1 (AngHV-1) recently renamed
Cyvirus anguillidallo 1). CyHV-1 and CyHV-3 infect common and koi carp
(Cyprinus carpio species); CyHV-2 infects goldfish, Crucian carp, and Gibel carp (all of which are
Carassius species); and AngHV-1 infects different anguillid eel species (
Anguilla). Notably, unlike cyprinids, anguillid eels are catadromous fish [
1]. Their lifecycle begins in the open ocean, with leptocephali larvae drifting thousands of kilometers across oceans to reach continental coastal waters, where they metamorphose into glass eels. These juvenile eels then migrate upstream towards freshwater habitats, where they grow into yellow eels over several years. Finally, they mature into silver eels and migrate back to the spawning site where they initially hatched to spawn before dying.
Since the first report of AngHV-1 in the 1980s, it has been detected globally, affecting different anguillid eel species from temperate to tropical countries [
2,
3]. It is causing economical losses in eel aquaculture [
4,
5] and is having a negative impact on wildlife. Despite their isolation in different eel species and from a broad geographic origin, AngHV-1 isolates were found to have a low genetic diversity [
6].
Infection with AngHV-1 causes severe hemorrhagic skin and gill lesions and an abnormal swimming posture [
7]. AngHV-1 disease is associated with high morbidity and with a mortality rate varying between eel species, for instance, 30% in American eels (
Anguilla rostrata) [
8] and up to 100% for short-finned eels (
Anguilla bicolor) [
5]. In addition to its negative impact on the aquaculture sector, AngHV-1 has also been suggested as an important cause of the decline in the wildlife of anguillid eel species such as European eels (
Anguilla anguilla) [
9,
10]. The numbers of glass eels reaching European coasts now amount to only 1% of those estimated in the early 1980s. As a result of disease outbreaks and several other factors, European eels have been classified as critically endangered on the International Union for Conservation of Nature (IUCN) Red List of Threatened Species [
11,
12]. The potential impact of AngHV-1 on wild European eels together with its negative impact on this species in the aquaculture sector (with a mortality rate of up to 30% [
9]) stimulated the development of an efficacious vaccine compatible with mass vaccination.
To date, there is no vaccine against AngHV-1 available on the market [
9]. Current measures to prevent AngHV-1 disease within aquaculture settings mainly rely, when possible, on shifting water temperatures outside of the range (below 22 °C) associated with efficient lytic replication and clinical disease [
13]. This approach acts as an effective way to reduce the clinical symptoms of infected eels and can reduce economic losses. However, it promotes latent infection [
14], thereby increasing the risk of transmission when latently infected eels are latter cohabiting with naïve eels under stressing conditions [
15]. Thus, fish originating from such facilities, including those used in restocking programs, could be a potential source for AngHV-1’s spread to wildlife [
16]. Only a few studies address the development of AngHV-1 candidate vaccines. Lately, a formalin-inactivated AngHV-1 vaccine tested in American eels (
Anguilla rostrata) was reported effective in inducing high levels of specific antibody and protection against a challenge [
17]. However, this inactivated vaccine requires two intramuscular injections per fish. It is therefore incompatible with the mass vaccination of eels and with the vaccination of relatively small subjects. The development of a safe and efficacious attenuated recombinant vaccine could circumvent these limitations. This was the main goal of the present study.
Recently, we developed an attenuated recombinant vaccine against CyHV-3 using prokaryotic recombination technologies and in vivo bioluminescent imaging system (IVIS) [
18]. The development of this vaccine relied on the deletion of CyHV-3 ORF56 and ORF57 [
18]. This candidate vaccine was shown to exhibit interesting properties such as, efficient replication in a cell culture (even if reduced compared to the parental wild-type strain), a good safety profile in juvenile carp, and the ability to induce protective immunity at the portal of entry. Further studies demonstrated that the deletion of CyHV-3 ORF57 was sufficient to induce this safety-efficacy profile [
19].
Orthologues of CyHV-3 ORF57 exist in CyHV-1 and CyHV-2 (ORF57) and in AngHV-1 (ORF 35) [
19,
20]. The roles of these orthologues are still unknown. The effect of ORF57 deletion on CyHV-2 infection has been tested in vitro and in vivo using a recombinant strain in which ORF57 was replaced by an expression cassette encoding a transgenic antigen [
21]. Surprisingly, and in contrast to what was observed for CyHV-3, ORF57 deletion did not impair CyHV-2 replication in a cell culture and induced only a mild reduction of virulence in vivo. Together, these results suggest that CyHV-3 ORF57 orthologues encoded by cypriniviruses express different biological roles despite their phylogenetic relationship.
Here, we studied the effect of ORF35 deletion on the ability of AngHV-1 to replicate in cell culture and on its virulence after inoculation of yellow eels by different routes. These experiments demonstrated that ORF35 deletion does not affect the production of AngHV-1 virions in cell culture but led to an abortive infection in vivo. Next, we studied the potential of an AngHV-1 ORF35-deleted recombinant as a vaccine candidate for the mass vaccination of yellow eels by immersion in water containing the virus. Exposure to the AngHV-1 ORF35-deleted recombinant induced a protective immune response against a wild-type challenge. This protection was shown to be dose-dependent and to rely on the infectivity of the AngHV-1 ORF35-deleted recombinant. This study suggests that the AngHV-1 ORF35 protein has singular properties compared to its orthologues encoded by CyHV-2 and CyHV-3. It also supports the potential of AngHV-1 ORF35-deleted recombinants for the mass vaccination of eels by immersion.
2. Materials and Methods
2.1. Cells and AngHV-1 Strains
Eel kidney (EK-1) cells were cultured as described previously [
6]. The AngHV-1 isolate (hereafter called the UK strain) used in this study was kindly provided by Dr Keith Way (Centre for Environment, Fisheries, and Aquaculture Science, United Kingdom). The recombinant AngHV-1 UK Luc strain was produced by homologous directed recombination (HDR) using the UK strain as a parental strain in a recent study (Delrez et al., manuscript submitted for publication). The UK Luc strain encodes a LucGFP cassette inserted in the intergenic region ORF32–ORF33 of the AngHV-1 genome between the coordinates 49,134 and 49,135 (MW580855.1) (
Figure 1). The LucGFP cassette consists of an EF1 promoter driving the transcription of a bicistronic mRNA-encoding firefly luciferase 2 (LUC2) and copepod GFP (copGFP) proteins linked by a T2A peptide (
Figure 1C).
2.2. Production of Recombinant Strains of AngHV-1 Deleted for ORF35 by HDR in Eukaryotic Cells
The UK ORF35 Del and UK Luc ORF35 Del strains were produced by HDR in EK-1 cells using the UK and the UK Luc strains as parental strains, respectively (
Figure 1). The pGEMT mCherry vector containing the recombination fragment consisted of the mCherry ORF flanked by 500 bp sequences, corresponding to the end of AngHV-1 ORF34 for the left homology region and the ORF35–ORF36 intergenic region plus the end of ORF36 for the right homology region. One day after transfection with the pGEMT mCherry vector, EK-1 cells were infected with AngHV-1 UK or UK Luc strains at a multiplicity of infection (MOI) of 0.01 plaque forming unit (pfu)/cell. Four days later, the supernatant was collected and diluted to infect naive EK-1 cells. Infected cells were overlaid with a medium containing carboxymethylcellulose (CMC) [
6]. Viral plaques expressing mCherry were picked and amplified until we obtained 100% plaque-expressing mCherry.
2.3. Genetic Characterization of AngHV-1 Recombinants
The molecular structures of all recombinant strains were confirmed by monitoring SacI restriction fragment length polymorphism by agarose gel electrophoresis, PCR of the recombination loci, and full-length genome sequencing, as described previously [
6].
2.4. Transcriptional Analyses
EK-1 cells were mock-infected or infected at an MOI of 0.1 pfu/cell. Twenty-four hours post infection (pi), RNA was isolated using the NucleoSpin RNA Mini kit (Macherey-Nagel, Düren, Germany), and residual DNA was removed using the TURBO DNA-free Kit (Invitrogen, Waltham, MA, USA). Reverse transcriptase (RT) reactions were performed on 5 µg of RNA using Superscript III Reverse Transcriptase and with oligo(dT) primers (Invitrogen) to generate cDNA. ORF32, ORF33, ORF34, ORF35, ORF36, and ORF55 (AngHV-1 DNA polymerase, based on Rijsewijk et al. [
22]) were amplified using the pairs of primers listed in
Table S1 using Phusion High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA). To exclude amplification from contaminant viral genomic DNA in purified RNA, PCR reactions were performed when RT was omitted from the reactions.
2.5. Indirect Immunofluorescence Staining
Cells were fixed in phosphate-buffered saline (PBS) containing 4% (
w/
v) paraformaldehyde (PAF) at 4 °C for 15 min and then 20 °C for 15 min. After washing with PBS, samples were permeabilized in PBS containing 0.1% (
v/
v) NP-40 at 37 °C for 15 min. Immunofluorescent staining (incubation and washes) was performed in PBS containing 10% fetal calf serum (FCS) (
v/
v) (PBS–FCS). Rabbit polyclonal antibodies (pAbs) raised against AngHV-1-purified virions (diluted 1:2000), following a procedure similar to He et al. [
23], were used as the primary antibody. The primary antibody was incubated at 37 °C for 1 h. After washing with PBS–FCS, Alexa Fluor 488 goat anti-rabbit immunoglobulin G (H+L) (Invitrogen) was used as the secondary antibody (diluted 1:1000) in PBS–FCS. The secondary antibody was incubated at 37 °C for 30 min. After washing with PBS–FCS, cells were incubated with PBS containing DAPI (dilute 1:2000) (ThermoFisher, Waltham, MA, USA) at room temperature for 5 min then washed with PBS before mounting.
2.6. Viral Growth Assay
Triplicate cultures of EK-1 cells were infected with AngHV-1 at an MOI of 0.01 pfu/cell. After an incubation period of 2 h, the cells were washed with PBS and overlaid with culture medium. The cell supernatant was collected at successive intervals. After centrifugation at 900×
g for 30 min at 4 °C to pellet cell debris, the supernatant was collected and stored at −80 °C. Viral titration was carried out by triplicate plaque assays in EK-1 cells, as described previously [
6].
2.7. Viral-Plaque-Area Assay
Viral-plaque-area assays were performed, as described previously [
6]. Individual plaques were revealed by immunofluorescent staining and imaged using a Nikon A1R confocal microscope, and areas were measured using the ImageJ software [
24].
2.8. Viral Photoinactivation by Psoralen/UV Treatment
To inactivate the UK ORF35 Del recombinant strain without affecting viral structural proteins (and, consequently, the ability of the virus to enter cells susceptible to AngHV-1 infection), virions were submitted to a treatment associating incubation with psoralen (4′-Aminomethyltrioxsalen hydrochloride, Sigma-Aldrich, St. Louis, MO, USA) and exposure to long-wave UV light (365 nm, 6 W, 0.16 A, UVP UVL-56, Analytik Jena, USA). In brief, 1 × 105 pfu of UK ORF35 Del were incubated in 1 mL of L-15 medium containing 5 µg/mL of psoralen and incubated on ice in a 35 mm sterile plastic Petri dish under UV light for 10 min at a distance of 5 cm. The efficiency of viral inactivation by psoralen/UV treatment was controlled by titration of residual infectious viral particles on EK-1 cells.
2.9. Fish
European eels at the glass eel developmental stage were obtained from an accredited commercial company (Foucher Maury, Paimboeuf, France). Microbiological, parasitic, and clinical examinations were conducted immediately after arrival in the animal facility and then on a monthly basis to control fish health. Glass eels were grown in 40 L freshwater tanks maintained at 25 °C. Fish were used at the stage of yellow eel.
2.10. AngHV-1 Inoculation Modes
Different modes of inoculation were used in this study. (i) Inoculation by intraperitoneal (IP) injection: Eels were anesthetized by immersion in water containing benzocaine (25 mg/L of water). A volume of 20 µL of a culture medium containing 2 × 105 pfu of AngHV-1 was injected intraperitoneally using a 0.3 mL insulin syringe (BD Micro-Fine). After injection, fish were placed in a recovery bath, then returned to their tanks. (ii) Inoculation by immersion in infectious water: fish were inoculated by immersion in water containing AngHV-1 (doses used (pfu/mL) are described in the figure legends) for 2 h under constant aeration. (iii) Inoculation by intradermic infection: Eels were anesthetized by immersion in water containing benzocaine (25 mg/L of water). Intradermal injections were administered using an electronic tattooing device. As part of this process, 20 µL of a culture medium containing 2 × 105 pfu of AngHV-1 was added into a sterile tattoo needle ink reservoir. Using this device, inoculum was delivered intradermally at three sites (all on the left side of the body, including the front, middle, and end) in a linear pattern along a length of approximately 1 cm per site. After intradermal injections, the fish were placed in a recovery bath, then returned to their tanks.
2.11. Ethical Statement
The experiments, maintenance, and care of the fish complied with the guidelines of the European Convention for the Protection of Vertebrate Animals used for experimental and other Scientific Purposes (CETS n° 123). The animal studies were approved by the local ethics committee of the University of Liège, Belgium (laboratory accreditation no., 1610008; protocol no., 1896). All efforts were made to apply the “3Rs rules” to reduce the number of subjects used to minimize suffering and to improve fish welfare. Of note, the present study respected strict ending-points, implying that fish were euthanized before natural death. As a consequence, the present study did not rely on the read-out of the mortality rate.
2.12. Bioluminescent Imaging
Firefly (
Photinus pyralis) luciferase activity was imaged using an IVIS (IVIS spectrum, PerkinElmer, Waltham, MA, USA), as described previously [
18,
25]. For cell culture analyses, the culture medium was replaced with a fresh medium containing D-luciferin (150 μg/mL) (Caliper LifeSciences, Hopkinton, MA, USA). Analyses were performed after an incubation period of 10 min at room temperature. For in vivo analyses, fish were anesthetized with benzocaine (25 mg/L of water). Fifteen minutes before a bioluminescence analysis, D-luciferin (150 mg/kg of body weight) was injected into the peritoneal cavity. The fish were analyzed in vivo lying on their right and left sides and ex vivo after euthanasia with benzocaine (250 mg/L of water). Dissected organs were analyzed independently from the body. All images were acquired using a maximum auto-exposure time of 1 min, a binning factor of 8, and a f/stop of 1. The relative intensities of transmitted light from bioluminescence were determined automatically and represented as a pseudo-color image ranging from violet (least intense) to red (most intense) using the Living Image 4.7.3 software. Regions of interest (ROIs) were drawn manually by tracing the organs or body outlines, and the average radiance (p/sec/cm
2/sr) was taken as the final measure of the bioluminescence emitted over the ROI. For the skin, the average radiance was measured on both sides of the body, and the results for individual fish were expressed as the mean of both sides. For the gills (mean of left and right gills) and internal organs, the analysis was performed ex vivo and separately. The cut-off for positivity was based on the mean + 3 SD of the values obtained for mock-infected fish (not represented in figures). For cell monolayers, the entire well was used as the ROI, and photon flux was measured in photons/sec (p/sec).
2.13. Statistical Analyses
Residuals for each dataset were first tested for normality using the Shapiro–Wilk test (GraphPad Prism v8.0.1). Omnibus tests on data on viral growth, plaque size, and bioluminescence (
Figure 2C–E) were conducted using either two-way ANOVA (GraphPad Prism v8.0.1) for datasets exhibiting a Gaussian distribution or Durbin tests for datasets exhibiting a non-Gaussian distribution (with the PMCMRplus package (v1.9.6) [
26] in R (v4.2.2) [
27]). Post-hoc multiple comparisons between groups of interest were made using either Sidak tests (two groups) or pairwise Tukey tests (more than two groups) (Graphpad Prism v8.0.1) for data exhibiting a Gaussian distribution and for data exhibiting a non-Gaussian distribution (using the wilcox.test function, a part of the R core package). The variables used for each omnibus test and their significance are described in the figure legends. The IVIS measurements in
Figure 3 were compared using an unpaired
t-test (two-tail) or a Wilcoxon test, as appropriate. The number of positive fish per group was compared between strains using Fisher–Pitman permutation test (using the coin package (v1.4.3) [
28] in R). For the IVIS measurements in
Figure 4, a non-parametric Kruskal–Wallis test was adopted, followed by controlling the False Discovery Rate (FDR) using the two-stage step-up method of Benjamini, Krieger, and Yekutieli (Graphpad Prism v8.0.1). The positive number of fish from each group was compared with a primary mock-infected group using the Fisher–Pitman permutation test. Results are indicated in each corresponding figure, with the statistical significance of all test results represented using the following symbols: *,
p < 0.05; **
p < 0.01; ***
p < 0.001.
4. Discussion
To date, despite its negative impact on eel aquaculture and wild eel populations, there is no effective vaccine against AngHV-1 available on the market. Control of AngHV-1 disease by shifting water temperatures below 22 °C to reduce lytic viral replication and associated clinical symptoms, including mortalities, can reduce the impact of the disease. However, it has the disadvantage to generate latently infected carriers that would inevitably reactivate the infection later in life, causing the re-emergence of disease symptoms and a transmission of the virus to naïve subjects [
30]. This may be especially detrimental when farmed eels are used in restocking programs of wild habitats. Consequently, there is a need for a safe and efficacious vaccine against AngHV-1 that is compatible with the mass vaccination of eels. Live attenuated vaccines represent the favored option for the development of a vaccine compatible with mass vaccination. The rational design of the development of an attenuated virus vaccine relies on the identification of non-essential viral genes playing a key role in virulence. A major barrier towards this process with AngHV-1 is the fact that there have been, to date, no studies conducted on the function of any of its genes.
Here, based on the results published on its orthologue encoded by CyHV-3, we identified and tested AngHV-1 ORF35 as a potential gene candidate for the production of a live attenuated recombinant vaccine [
18,
19,
20]. Analyses of ORF35-deleted recombinants led to the following observations: (i) AngHV-1 ORF35 is not essential for viral growth in cell culture, and its deletion does not affect the production of extracellular virions despite reducing the size of the viral plaque. (ii) AngHV-1 ORF35 is an essential virulence factor, and its deletion led to abortive infection in vivo. (iii) Inoculation of an infectious AngHV-1 ORF35-deleted recombinant by immersion induced a protective immune response against a wild-type challenge in a dose-dependent manner. This study suggests that AngHV-1 ORF35 has singular functions compared to its orthologues encoded by CyHV-2 and CyHV-3. It also supports the potential of AngHV-1 ORF35-deleted recombinants for the mass vaccination of eels by immersion.
Orthologues of AngHV-1 ORF35 are encoded by other Cypriniviruses (ORF57 of CyHV-1, -2, and -3). Including the results of the present study, the impact of the deletion of these orthologues on virus replication has been tested in cell culture and in vivo for three cypriniviruses: CyHV-3 [
18,
19], CyHV-2 [
21], and AngHV-1 (present study). These studies identified consistently these orthologues as non-essential genes for replication in cell culture. However, they also suggested that these orthologues encode different functions or at least functions of different importance in the biological cycle of these viruses. This conclusion is supported by observations performed both in vitro and in vivo. In vitro deletion of CyHV-3 ORF57 induced a drastic reduction in virion production in cell culture, while the deletion of the orthologue had no impact on CyHV-2 [
21] or AngHV-1 (
Figure 2C,E). Similarly, in vivo experiments revealed different phenotypes, with deletion of the orthologue in CyHV-3, CyHV-2, and AngHV-1 inducing strong attenuation, marginal attenuation, and abortive infection, respectively. Different non-exclusive hypotheses could explain the different phenotypes observed among cypriniviruses. The first obvious hypothesis is that the different orthologues acquired different functions since divergence from their common ancestor. A second hypothesis could be that the functions mediated by the orthologues could be redundant in some viruses (with deletions compensatedby other viral proteins) while being non-redundant and, therefore, essential in other viruses. According to this hypothesis, the deletion of the orthologue could mediate either no/minor phenotypes or a strong phenotype. Other hypotheses could rely on host-cell factors rather than on functional redundancy or functional diversity among viral genes. For example, it could be possible that in certain hosts, some cellular protein(s) can trans-complement the functions of deleted viral orthologues. Finally, assuming that the AngHV-1 ORF35 orthologues are proteins involved in the immune evasion of host innate immunity, the different phenotypes observed in vitro and in vivo could reveal the absence or variable importance of the innate immune component targeted by the viral orthologues in the different host models. Further studies are required to unravel the functions of the orthologues of AngHV-1 ORF35. These projects of comparative virology are likely to unravel fascinating aspects of host-virus evolution.
The present study revealed the potential of AngHV-1 ORF35-deleted recombinants as a vaccine candidate for the mass vaccination of eels by immersion. Surprisingly, despite the abortive infection observed after inoculation by immersion in infectious water, the protective immune response induced by the vaccine was shown to be dependent on virus infectivity and subject to a dose–effect relationship. These results suggest that the abortive infection is essential for antigen presentation and/or stimulation of the innate immune response to induce the protection observed. The abortive infection observed in vivo for the AngHV-1 ORF35-deleted recombinant is surprising for two reasons. First, because deletion of the orthologue of AngHV-1 ORF35 in CyHV-2 and CyHV-3 led, respectively, to mild attenuation and strong attenuation but not to abortive infection [
18,
21]. Second, because deletion of the ORF35 gene had no negative impact on AngHV-1 virion production in a cell culture (
Figure 2C,E). Some of the hypotheses discussed above may consolidate the results observed in vitro and in vivo for the AngHV-1 ORF35-deleted recombinant. The dispensable nature of ORF35 for efficient replication in EK-1 cells, while it is essential for infection in vivo, could manifest the expression in EK-1 cells but not in host cells in vivo of a cellular protein trans-complementing the deletion of ORF35. A second and preferred hypothesis could be that ORF35 is essential in vivo to block an innate antiviral immune mechanism that is not functional in EK-1 cells. Experiments are currently ongoing to address these hypotheses.
The candidate vaccine developed in this study is compatible with the mass vaccination of eels by immersion. It could be used to control AngHV-1 infection both in the context of eel aquaculture and eel conservation programs. Due to their complex lifecycle, anguillid eels cannot be bred in captivity. Consequently, all anguillid eels produced by the aquaculture sector or used in restocking programs of wild habitats rely on wild-caught stock of glass eels. Recent studies performed on European eels suggested that glass eels enter estuaries free of AngHV-1 and then become infected in fresh water when they mature to the yellow and silver stages [
31]. The present study was performed on yellow eels. It will be interesting to determine, in future experiments, whether the candidate vaccine developed in this study can be used to vaccine glass eels successfully by immersion. Of note, glass eels have been shown to be immune-competent and able to mount an adaptive immune response after vaccination [
32]. If successful, vaccination could be applied to glass eels maintained in facilities free of AngHV-1, before their transfer after the onset of immunity to farms and to a wild habitat. In the latter case, we hope that the vaccination could contribute to an increase in the number of eels that successfully reach a spawning area and reproduce by reducing the negative impact of AngHV-1 on endangered eel species.